MA53427B1 - Inhibiteurs de l'arginase et leurs méthodes d'utilisation - Google Patents
Inhibiteurs de l'arginase et leurs méthodes d'utilisationInfo
- Publication number
- MA53427B1 MA53427B1 MA53427A MA53427A MA53427B1 MA 53427 B1 MA53427 B1 MA 53427B1 MA 53427 A MA53427 A MA 53427A MA 53427 A MA53427 A MA 53427A MA 53427 B1 MA53427 B1 MA 53427B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- arginase inhibitors
- boraspiro
- dodecan
- aza
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721113P | 2018-08-22 | 2018-08-22 | |
| PCT/EP2019/072341 WO2020038983A1 (en) | 2018-08-22 | 2019-08-21 | Arginase inhibitors and methods of use thereof |
| EP19758683.7A EP3840837B1 (en) | 2018-08-22 | 2019-08-21 | Arginase inhibitors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53427A MA53427A (fr) | 2021-12-01 |
| MA53427B1 true MA53427B1 (fr) | 2024-06-28 |
Family
ID=67742403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53427A MA53427B1 (fr) | 2018-08-22 | 2019-08-21 | Inhibiteurs de l'arginase et leurs méthodes d'utilisation |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11952392B2 (enExample) |
| EP (2) | EP4371614A3 (enExample) |
| JP (1) | JP7441210B2 (enExample) |
| KR (1) | KR102668252B1 (enExample) |
| CN (1) | CN112584900B (enExample) |
| AU (1) | AU2019323663B2 (enExample) |
| CA (1) | CA3109100A1 (enExample) |
| CL (1) | CL2021000430A1 (enExample) |
| DK (1) | DK3840837T3 (enExample) |
| EA (1) | EA202190532A1 (enExample) |
| ES (1) | ES2980252T3 (enExample) |
| FI (1) | FI3840837T3 (enExample) |
| HR (1) | HRP20240694T1 (enExample) |
| HU (1) | HUE066903T2 (enExample) |
| IL (1) | IL280924B2 (enExample) |
| LT (1) | LT3840837T (enExample) |
| MA (1) | MA53427B1 (enExample) |
| MX (1) | MX2021002042A (enExample) |
| PL (1) | PL3840837T3 (enExample) |
| PT (1) | PT3840837T (enExample) |
| RS (1) | RS65608B1 (enExample) |
| SG (1) | SG11202101618PA (enExample) |
| SI (1) | SI3840837T1 (enExample) |
| SM (1) | SMT202400221T1 (enExample) |
| WO (1) | WO2020038983A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| MY206577A (en) * | 2019-02-08 | 2024-12-24 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| EP4239652A4 (en) | 2020-12-25 | 2024-06-05 | Sumitomo Riko Company Limited | Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| AU2016281620B2 (en) * | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| US11291674B2 (en) * | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US12215116B2 (en) | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| WO2019205979A1 (zh) | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
-
2019
- 2019-08-21 MA MA53427A patent/MA53427B1/fr unknown
- 2019-08-21 PL PL19758683.7T patent/PL3840837T3/pl unknown
- 2019-08-21 SI SI201930758T patent/SI3840837T1/sl unknown
- 2019-08-21 RS RS20240642A patent/RS65608B1/sr unknown
- 2019-08-21 CA CA3109100A patent/CA3109100A1/en active Pending
- 2019-08-21 EA EA202190532A patent/EA202190532A1/ru unknown
- 2019-08-21 KR KR1020217007915A patent/KR102668252B1/ko active Active
- 2019-08-21 EP EP24162089.7A patent/EP4371614A3/en active Pending
- 2019-08-21 FI FIEP19758683.7T patent/FI3840837T3/fi active
- 2019-08-21 CN CN201980055111.3A patent/CN112584900B/zh active Active
- 2019-08-21 ES ES19758683T patent/ES2980252T3/es active Active
- 2019-08-21 HR HRP20240694TT patent/HRP20240694T1/hr unknown
- 2019-08-21 IL IL280924A patent/IL280924B2/en unknown
- 2019-08-21 WO PCT/EP2019/072341 patent/WO2020038983A1/en not_active Ceased
- 2019-08-21 EP EP19758683.7A patent/EP3840837B1/en active Active
- 2019-08-21 PT PT197586837T patent/PT3840837T/pt unknown
- 2019-08-21 JP JP2021509794A patent/JP7441210B2/ja active Active
- 2019-08-21 DK DK19758683.7T patent/DK3840837T3/da active
- 2019-08-21 AU AU2019323663A patent/AU2019323663B2/en active Active
- 2019-08-21 SM SM20240221T patent/SMT202400221T1/it unknown
- 2019-08-21 LT LTEPPCT/EP2019/072341T patent/LT3840837T/lt unknown
- 2019-08-21 US US17/269,569 patent/US11952392B2/en active Active
- 2019-08-21 HU HUE19758683A patent/HUE066903T2/hu unknown
- 2019-08-21 MX MX2021002042A patent/MX2021002042A/es unknown
- 2019-08-21 SG SG11202101618PA patent/SG11202101618PA/en unknown
-
2021
- 2021-02-19 CL CL2021000430A patent/CL2021000430A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551379A1 (en) | Substituted tetrahydrofurans as modulators of sodium channels | |
| EP4643882A3 (en) | Capsid inhibitors for the prevention of hiv | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
| MX2021006265A (es) | Derivados de panteteina y usos de los mismos. | |
| MA47301B1 (fr) | Inhibiteurs sélectifs de jak1 | |
| MA43116B1 (fr) | Ditosylate de valbénazine et polymorphes associés | |
| MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MX2024013020A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| EP4696380A3 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| CR20240514A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MX2023010540A (es) | Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. | |
| MX2020008929A (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico. | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MX372773B (es) | Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico. | |
| MY191183A (en) | (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| PH12018501876A1 (en) | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| WO2020232330A8 (en) | Inhibiting agents for bruton's tyrosine kinase | |
| MX2020007494A (es) | Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas. |